Cangrelor versus crushed ticagrelor in patients with acute
myocardial infarction and cardiogenic shock: rationale and
design of the randomised, double-blind DAPT-SHOCK-AMI trial

J 2024

Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial

MOTOVSKA, Zuzana; Ota HLINOMAZ; Jan MROZEK; Petr KALA; Tobias GEISLER et. al.

Základní údaje

Originální název

Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial

Autoři

MOTOVSKA, Zuzana (203 Česká republika); Ota HLINOMAZ (203 Česká republika, domácí); Jan MROZEK (203 Česká republika); Petr KALA (203 Česká republika, domácí); Tobias GEISLER; Milan HROMADKA (203 Česká republika); Ibrahim AKIN (203 Česká republika); Jan PRECEK (203 Česká republika); Jiri KETTNER (203 Česká republika); Pavel CERVINKA (203 Česká republika); Gilles MONTALESCOT; Jiří JARKOVSKÝ (203 Česká republika, domácí); Jan BELOHLAVEK (203 Česká republika); Josef BIS (203 Česká republika); Jan MATEJKA (203 Česká republika); Alexandra VODZINSKA (203 Česká republika); Tamilla MUZAFAROVA (203 Česká republika); Pavol TOMASOV (203 Česká republika); Alexander SCHEE; Stanislav BARTUS (203 Česká republika); Andrea ANDRASOVA (203 Česká republika); Christoph B OLIVIER; Ales KOVARIK (203 Česká republika); Petr OSTADAL; Regina DEMLOVÁ (203 Česká republika, domácí); Lenka SOUČKOVÁ (203 Česká republika, domácí); Ivan VULEV; Zdenek COUFAL; Janusz KOCHMAN; Iuri MARINOV; Jacek KUBICA; Gregory DUCROCQ; Michal KARPISEK (203 Česká republika); Zdenek KLIMSA (203 Česká republika); Martin HUDEC (203 Česká republika); Petr WIDIMSKY (203 Česká republika) a Deepak L BHATT

Vydání

Eurointervention, Toulouse, Europa edition, 2024, 1774-024X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Francie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

DAPT-SHOCK AMI

Impakt faktor

Impact factor: 7.800 v roce 2023

Kód RIV

RIV/00216224:14110/24:00138221

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.4244/EIJ-D-24-00203

UT WoS

001367392800008

EID Scopus

2-s2.0-85207594400

Klíčová slova česky

adjunctive pharmacotherapy; cardiogenic shock; clinical trials; STEMI

Klíčová slova anglicky

adjunctive pharmacotherapy; cardiogenic shock; clinical trials; STEMI

Štítky

14110115, 14110132, 14110211, 14110516, 14119612, CZECRIN, Excelence Science, FN KV, operator, RIV, článek v časopise

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 4. 4. 2025 13:20, Mgr. Tereza Miškechová

Anotace

V originále

Cardiogenic shock (CS) is a devastating and fatal complication of acute myocardial infarction (AMI). CS can affect the pharmacokinetics and pharmacodynamics of medications. The unique properties of cangrelor make it the optimal P2Y12 inhibitor for CS-AMI, in terms of both efficacy and safety. The DAPT-SHOCK-AMI trial (ClinicalTrials. gov: NCT03551964; EudraCT: 2018-002161-19) will assess the benefits of cangrelor in patients with an initial CS-AMI undergoing primary angioplasty. This randomised, multicentre, placebo-controlled trial of approximately 550 patients (with an allowed 10% increase) in 5 countries using a double-blind design will compare initial P2Y12 inhibitor treatment strategies in patients with CS-AMI of (A) intravenous cangrelor and (B) ticagrelor administered as crushed tablets at a loading dose of 180 mg. The primary clinical endpoint is a composite of all-cause death, myocardial infarction (MI), or stroke within 30 days. The main secondary endpoints are (1) the net clinical endpoint, defined as death, MI, urgent revascularisation of the infarct-related artery, stroke, or major bleeding as defined by the Bleeding Academic Research Consortium criteria; (2) cardiovascular-related death, MI, urgent revascularisation, or heart failure; (3) heart failure; and (4) cardiovascular-related death, all (1-4) within 1 year after study enrolment. A platelet reactivity study that tests the laboratory antiplatelet benefits of cangrelor, when given in addition to standard antiplatelet therapy, will be conducted using vasodilator-stimulated phosphoprotein phosphorylation. The primary laboratory endpoints are the periprocedural rate of onset and the proportion of patients who achieve effective P2Y12 inhibition. The DAPT-SHOCK-AMI study is the first randomised trial to evaluate the benefits of cangrelor in patients with CS-AMI.

Návaznosti

LM2023049, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN - Czech National Node to the European Clinical Research Infrastructure Network

LX22NPO5104, projekt VaV

Název: Národní institut pro výzkum metabolických a kardiovaskulárních onemocnění (Akronym: CarDia)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Národní institut pro léčbu metabolických a kardiovaskulárních onemocnění, 5.1 EXCELES

NV19-02-00086, projekt VaV

Název: Duální protidestičková léčba pacientů s akutním infarktem myokardu v kardiogenním šoku - studie DAPT-SHOCK AMI

Investor: Ministerstvo zdravotnictví ČR, Duální protidestičková léčba pacientů s akutním infarktem myokardu v kardiogenním šoku - studie DAPT-SHOCK AMI

Citovat

MOTOVSKA, Zuzana; Ota HLINOMAZ; Jan MROZEK; Petr KALA; Tobias GEISLER; Milan HROMADKA; Ibrahim AKIN; Jan PRECEK; Jiri KETTNER; Pavel CERVINKA; Gilles MONTALESCOT; Jiří JARKOVSKÝ; Jan BELOHLAVEK; Josef BIS; Jan MATEJKA; Alexandra VODZINSKA; Tamilla MUZAFAROVA; Pavol TOMASOV; Alexander SCHEE; Stanislav BARTUS; Andrea ANDRASOVA; Christoph B OLIVIER; Ales KOVARIK; Petr OSTADAL; Regina DEMLOVÁ; Lenka SOUČKOVÁ; Ivan VULEV; Zdenek COUFAL; Janusz KOCHMAN; Iuri MARINOV; Jacek KUBICA; Gregory DUCROCQ; Michal KARPISEK; Zdenek KLIMSA; Martin HUDEC; Petr WIDIMSKY a Deepak L BHATT. Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial. Eurointervention. Toulouse: Europa edition, 2024, roč. 20, č. 20, s. "e1309"-"e1318", 15 s. ISSN 1774-024X. Dostupné z: https://dx.doi.org/10.4244/EIJ-D-24-00203.

@article{2464301,
   author = {Motovska, Zuzana and Hlinomaz, Ota and Mrozek, Jan and Kala, Petr and Geisler, Tobias and Hromadka, Milan and Akin, Ibrahim and Precek, Jan and Kettner, Jiri and Cervinka, Pavel and Montalescot, Gilles and Jarkovský, Jiří and Belohlavek, Jan and Bis, Josef and Matejka, Jan and Vodzinska, Alexandra and Muzafarova, Tamilla and Tomasov, Pavol and Schee, Alexander and Bartus, Stanislav and Andrasova, Andrea and Olivier, Christoph B and Kovarik, Ales and Ostadal, Petr and Demlová, Regina and Součková, Lenka and Vulev, Ivan and Coufal, Zdenek and Kochman, Janusz and Marinov, Iuri and Kubica, Jacek and Ducrocq, Gregory and Karpisek, Michal and Klimsa, Zdenek and Hudec, Martin and Widimsky, Petr and Bhatt, Deepak L},
   article_location = {Toulouse},
   article_number = {20},
   doi = {http://dx.doi.org/10.4244/EIJ-D-24-00203},
   keywords = {adjunctive pharmacotherapy; cardiogenic shock; clinical trials; STEMI},
   language = {eng},
   issn = {1774-024X},
   journal = {Eurointervention},
   title = {Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial},
   url = {https://eurointervention.pcronline.com/article/cangrelor-versus-crushed-ticagrelor-in-patients-with-acute-myocardial-infarction-and-cardiogenic-shock-rationale-and-design-of-the-randomised-double-blind-dapt-shock-ami-trial},
   volume = {20},
   year = {2024}
}

TY  - JOUR
ID  - 2464301
AU  - Motovska, Zuzana - Hlinomaz, Ota - Mrozek, Jan - Kala, Petr - Geisler, Tobias - Hromadka, Milan - Akin, Ibrahim - Precek, Jan - Kettner, Jiri - Cervinka, Pavel - Montalescot, Gilles - Jarkovský, Jiří - Belohlavek, Jan - Bis, Josef - Matejka, Jan - Vodzinska, Alexandra - Muzafarova, Tamilla - Tomasov, Pavol - Schee, Alexander - Bartus, Stanislav - Andrasova, Andrea - Olivier, Christoph B - Kovarik, Ales - Ostadal, Petr - Demlová, Regina - Součková, Lenka - Vulev, Ivan - Coufal, Zdenek - Kochman, Janusz - Marinov, Iuri - Kubica, Jacek - Ducrocq, Gregory - Karpisek, Michal - Klimsa, Zdenek - Hudec, Martin - Widimsky, Petr - Bhatt, Deepak L
PY  - 2024
TI  - Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial
JF  - Eurointervention
VL  - 20
IS  - 20
SP  - "e1309"-"e1318"
EP  - "e1309"-"e1318"
PB  - Europa edition
SN  - 1774024X
KW  - adjunctive pharmacotherapy
KW  - cardiogenic shock
KW  - clinical trials
KW  - STEMI
UR  - https://eurointervention.pcronline.com/article/cangrelor-versus-crushed-ticagrelor-in-patients-with-acute-myocardial-infarction-and-cardiogenic-shock-rationale-and-design-of-the-randomised-double-blind-dapt-shock-ami-trial
N2  - Cardiogenic shock (CS) is a devastating and fatal complication of acute myocardial infarction (AMI). CS can affect the pharmacokinetics and pharmacodynamics of medications. The unique properties of cangrelor make it the optimal P2Y12 inhibitor for CS-AMI, in terms of both efficacy and safety. The DAPT-SHOCK-AMI trial (ClinicalTrials. gov: NCT03551964; EudraCT: 2018-002161-19) will assess the benefits of cangrelor in patients with an initial CS-AMI undergoing primary angioplasty. This randomised, multicentre, placebo-controlled trial of approximately 550 patients (with an allowed 10% increase) in 5 countries using a double-blind design will compare initial P2Y12 inhibitor treatment strategies in patients with CS-AMI of (A) intravenous cangrelor and (B) ticagrelor administered as crushed tablets at a loading dose of 180 mg. The primary clinical endpoint is a composite of all-cause death, myocardial infarction (MI), or stroke within 30 days. The main secondary endpoints are (1) the net clinical endpoint, defined as death, MI, urgent revascularisation of the infarct-related artery, stroke, or major bleeding as defined by the Bleeding Academic Research Consortium criteria; (2) cardiovascular-related death, MI, urgent revascularisation, or heart failure; (3) heart failure; and (4) cardiovascular-related death, all (1-4) within 1 year after study enrolment. A platelet reactivity study that tests the laboratory antiplatelet benefits of cangrelor, when given in addition to standard antiplatelet therapy, will be conducted using vasodilator-stimulated phosphoprotein phosphorylation. The primary laboratory endpoints are the periprocedural rate of onset and the proportion of patients who achieve effective P2Y12 inhibition. The DAPT-SHOCK-AMI study is the first randomised trial to evaluate the benefits of cangrelor in patients with CS-AMI.
ER  -

MOTOVSKA, Zuzana; Ota HLINOMAZ; Jan MROZEK; Petr KALA; Tobias GEISLER; Milan HROMADKA; Ibrahim AKIN; Jan PRECEK; Jiri KETTNER; Pavel CERVINKA; Gilles MONTALESCOT; Jiří JARKOVSKÝ; Jan BELOHLAVEK; Josef BIS; Jan MATEJKA; Alexandra VODZINSKA; Tamilla MUZAFAROVA; Pavol TOMASOV; Alexander SCHEE; Stanislav BARTUS; Andrea ANDRASOVA; Christoph B OLIVIER; Ales KOVARIK; Petr OSTADAL; Regina DEMLOVÁ; Lenka SOUČKOVÁ; Ivan VULEV; Zdenek COUFAL; Janusz KOCHMAN; Iuri MARINOV; Jacek KUBICA; Gregory DUCROCQ; Michal KARPISEK; Zdenek KLIMSA; Martin HUDEC; Petr WIDIMSKY a Deepak L BHATT. Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial. \textit{Eurointervention}. Toulouse: Europa edition, 2024, roč.~20, č.~20, s.~''e1309''-''e1318'', 15 s. ISSN~1774-024X. Dostupné z: https://dx.doi.org/10.4244/EIJ-D-24-00203.

Přehled o publikaci